These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 38724731)

  • 1. Influence of grandchildren on COVID-19 vaccination uptake among older adults in China: a parallel-group, cluster-randomized controlled trial.
    Bian J; Zhang W; Guo Z; Li X; Fu L; Lu Z; Fitzpatrick T; Sun Y; Gao Y; Chen Y; Liu Q; He L; Sun C; Zou H
    Nat Aging; 2024 May; 4(5):638-646. PubMed ID: 38724731
    [TBL] [Abstract][Full Text] [Related]  

  • 2. College students' influence on COVID-19 vaccination uptake among seniors in China: a protocol of combined cross-sectional and experimental study.
    Bian J; Guo Z; Zhang W; Li X; Sun C; Xu X; Zou H
    BMC Public Health; 2023 Jul; 23(1):1322. PubMed ID: 37430252
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Safety, tolerability, and immunogenicity of an aerosolised adenovirus type-5 vector-based COVID-19 vaccine (Ad5-nCoV) in adults: preliminary report of an open-label and randomised phase 1 clinical trial.
    Wu S; Huang J; Zhang Z; Wu J; Zhang J; Hu H; Zhu T; Zhang J; Luo L; Fan P; Wang B; Chen C; Chen Y; Song X; Wang Y; Si W; Sun T; Wang X; Hou L; Chen W
    Lancet Infect Dis; 2021 Dec; 21(12):1654-1664. PubMed ID: 34324836
    [TBL] [Abstract][Full Text] [Related]  

  • 4. COVID-19 vaccination uptake and determinants of booster vaccination among persons who inject drugs in New York City.
    Khezri M; McKnight C; Weng CA; Kimball S; Des Jarlais D
    PLoS One; 2024; 19(5):e0303394. PubMed ID: 38743729
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A randomized, double-blind, placebo-controlled phase III clinical trial to evaluate the efficacy and safety of SARS-CoV-2 vaccine (inactivated, Vero cell): a structured summary of a study protocol for a randomised controlled trial.
    Akova M; Unal S
    Trials; 2021 Apr; 22(1):276. PubMed ID: 33849629
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Young adults' intention to encourage COVID-19 vaccination among their grandparents: A nationwide cross-sectional survey of college students in China.
    Guo Z; Li X; Bian J; Zhang W; Lu Z; Sun Y; Gao Y; Fu L; Zou H
    Vaccine X; 2024 Jan; 16():100439. PubMed ID: 38283624
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effectiveness of booster vaccination with inactivated COVID-19 vaccines against SARS-CoV-2 Omicron BA.2 infection in Guangdong, China: a cohort study.
    He X; Zeng B; Wang Y; Pang Y; Zhang M; Hu T; Liang Y; Kang M; Tang S
    Front Immunol; 2023; 14():1257360. PubMed ID: 37915583
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Impacts of travel duration on urban-rural resident free vaccination behavior: Chinese COVID-19 vaccine booster dose evidence.
    Miao Y; Zhang J; Shen Z; Li Y; Zhang W; Bai J; Zhu D; Ren R; Guo D; Tarimo CS; Dong W; Zhao Q; Hu J; Li M; Liu R
    Hum Vaccin Immunother; 2024 Dec; 20(1):2352914. PubMed ID: 38845401
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The Efficacy of a Brief, Altruism-Eliciting Video Intervention in Enhancing COVID-19 Vaccination Intentions Among a Population-Based Sample of Younger Adults: Randomized Controlled Trial.
    Zhu P; Tatar O; Griffin-Mathieu G; Perez S; Haward B; Zimet G; Tunis M; Dubé È; Rosberger Z
    JMIR Public Health Surveill; 2022 May; 8(5):e37328. PubMed ID: 35544437
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials.
    Voysey M; Costa Clemens SA; Madhi SA; Weckx LY; Folegatti PM; Aley PK; Angus B; Baillie VL; Barnabas SL; Bhorat QE; Bibi S; Briner C; Cicconi P; Clutterbuck EA; Collins AM; Cutland CL; Darton TC; Dheda K; Dold C; Duncan CJA; Emary KRW; Ewer KJ; Flaxman A; Fairlie L; Faust SN; Feng S; Ferreira DM; Finn A; Galiza E; Goodman AL; Green CM; Green CA; Greenland M; Hill C; Hill HC; Hirsch I; Izu A; Jenkin D; Joe CCD; Kerridge S; Koen A; Kwatra G; Lazarus R; Libri V; Lillie PJ; Marchevsky NG; Marshall RP; Mendes AVA; Milan EP; Minassian AM; McGregor A; Mujadidi YF; Nana A; Padayachee SD; Phillips DJ; Pittella A; Plested E; Pollock KM; Ramasamy MN; Ritchie AJ; Robinson H; Schwarzbold AV; Smith A; Song R; Snape MD; Sprinz E; Sutherland RK; Thomson EC; Török ME; Toshner M; Turner DPJ; Vekemans J; Villafana TL; White T; Williams CJ; Douglas AD; Hill AVS; Lambe T; Gilbert SC; Pollard AJ;
    Lancet; 2021 Mar; 397(10277):881-891. PubMed ID: 33617777
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immunogenicity and safety of a booster dose of a self-amplifying RNA COVID-19 vaccine (ARCT-154) versus BNT162b2 mRNA COVID-19 vaccine: a double-blind, multicentre, randomised, controlled, phase 3, non-inferiority trial.
    Oda Y; Kumagai Y; Kanai M; Iwama Y; Okura I; Minamida T; Yagi Y; Kurosawa T; Greener B; Zhang Y; Walson JL
    Lancet Infect Dis; 2024 Apr; 24(4):351-360. PubMed ID: 38141632
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Safety, immunogenicity, and efficacy of the mRNA vaccine CS-2034 as a heterologous booster versus homologous booster with BBIBP-CorV in adults aged ≥18 years: a randomised, double-blind, phase 2b trial.
    Wu JD; Li JX; Liu J; Wang HM; Zhou GH; Li J; Wu D; Chen X; Feng Y; Qi XY; Wang X; Gou JB; Ma TL; Yang XY; Xu LF; Wan P; Zhu T; Wang ZF; Zhu FC;
    Lancet Infect Dis; 2023 Sep; 23(9):1020-1030. PubMed ID: 37216958
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine in healthy adults aged 18-59 years: a randomised, double-blind, placebo-controlled, phase 1/2 clinical trial.
    Zhang Y; Zeng G; Pan H; Li C; Hu Y; Chu K; Han W; Chen Z; Tang R; Yin W; Chen X; Hu Y; Liu X; Jiang C; Li J; Yang M; Song Y; Wang X; Gao Q; Zhu F
    Lancet Infect Dis; 2021 Feb; 21(2):181-192. PubMed ID: 33217362
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immunogenicity of COVID-19 booster vaccination in IEI patients and their one year clinical follow-up after start of the COVID-19 vaccination program.
    van Leeuwen LPM; Grobben M; GeurtsvanKessel CH; Ellerbroek PM; de Bree GJ; Potjewijd J; Rutgers A; Jolink H; van de Veerdonk FL; van Gils MJ; de Vries RD; Dalm VASH;
    Front Immunol; 2024; 15():1390022. PubMed ID: 38698851
    [TBL] [Abstract][Full Text] [Related]  

  • 15. COVID-19 booster vaccine uptake and reduced risks for long-COVID: A cross-sectional study of a U.S. adult population.
    Xie Z; Stallings-Smith S; Patel S; Case S; Hong YR
    Vaccine; 2024 Jun; 42(16):3529-3535. PubMed ID: 38670844
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Relative effectiveness of a heterologous booster dose with adenovirus type 5 vectored COVID-19 vaccine versus three doses of inactivated COVID-19 vaccine in adults during a nationwide outbreak of omicron predominance, in China: a retrospective, individually matched cohort-control study.
    Jia S; Yin Z; Pan H; Wang F; Liu X; Wang Q; Zhang L; Tang J; Yang H; Du J; Wang Z; Jin P; Peng Z; Tang R; Kang G; Wang X; Li S; Wang W; Li J; Shen H; Zhu F
    Emerg Microbes Infect; 2024 Dec; 13(1):2332660. PubMed ID: 38678636
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Enhancing COVID-19 booster vaccination among the elderly through text message reminders.
    Lee YC; Lee BH; Lin YH; Wu BJ; Chen TJ; Chen WM; Chen YC
    Hum Vaccin Immunother; 2024 Dec; 20(1):2375665. PubMed ID: 39016157
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Behavioral Intention to Receive a COVID-19 Vaccination Among Chinese Factory Workers: Cross-sectional Online Survey.
    Zhang KC; Fang Y; Cao H; Chen H; Hu T; Chen Y; Zhou X; Wang Z
    J Med Internet Res; 2021 Mar; 23(3):e24673. PubMed ID: 33646966
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Safety and immunogenicity of ChAdOx1 nCoV-19 vaccine administered in a prime-boost regimen in young and old adults (COV002): a single-blind, randomised, controlled, phase 2/3 trial.
    Ramasamy MN; Minassian AM; Ewer KJ; Flaxman AL; Folegatti PM; Owens DR; Voysey M; Aley PK; Angus B; Babbage G; Belij-Rammerstorfer S; Berry L; Bibi S; Bittaye M; Cathie K; Chappell H; Charlton S; Cicconi P; Clutterbuck EA; Colin-Jones R; Dold C; Emary KRW; Fedosyuk S; Fuskova M; Gbesemete D; Green C; Hallis B; Hou MM; Jenkin D; Joe CCD; Kelly EJ; Kerridge S; Lawrie AM; Lelliott A; Lwin MN; Makinson R; Marchevsky NG; Mujadidi Y; Munro APS; Pacurar M; Plested E; Rand J; Rawlinson T; Rhead S; Robinson H; Ritchie AJ; Ross-Russell AL; Saich S; Singh N; Smith CC; Snape MD; Song R; Tarrant R; Themistocleous Y; Thomas KM; Villafana TL; Warren SC; Watson MEE; Douglas AD; Hill AVS; Lambe T; Gilbert SC; Faust SN; Pollard AJ;
    Lancet; 2021 Dec; 396(10267):1979-1993. PubMed ID: 33220855
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Access to COVID-19 vaccination by socio-economic status in older Singaporean adults: a population-based cohort study.
    Wee LE; Yap AJW; Dickens B; Tan S; Ong B; Lye DC; Tan KB
    Public Health; 2024 Aug; 233():38-44. PubMed ID: 38850601
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.